Literature DB >> 23767434

Prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults.

Veljko Dubljević1.   

Abstract

This article analyzes appropriate public policies for enhancement use of two most important stimulant drugs: Ritalin (methylphenidate) and Adderall (mixed amphetamine salts). The author argues that appropriate regulation of cognition enhancement drugs cannot be a result of a general discussion on cognitive enhancements as such, but has to be made on a case-by-case basis. Starting from the recently proposed taxation approach to cognition enhancement drugs, the author analyzes available, moderately permissive models of regulation. After a thorough analysis of relevant characteristics of methylphenidate and amphetamine, the author concludes that a moderately liberal permissive regulation of enhancement use by healthy adults might be appropriate for extended release forms of methylphenidate. However, due to their danger profile, amphetamine and instant release forms of methylphenidate should not be made readily available to healthy adults and would need to be prohibited.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23767434     DOI: 10.1080/15265161.2013.794875

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  7 in total

Review 1.  Prescription stimulant medication misuse: Where are we and where do we go from here?

Authors:  Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

Review 2.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

3.  Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics.

Authors:  Sebastian Sattler; Guido Mehlkop; Peter Graeff; Carsten Sauer
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-01

4.  tDCS for Memory Enhancement: Analysis of the Speculative Aspects of Ethical Issues.

Authors:  Nathalie Voarino; Veljko Dubljević; Eric Racine
Journal:  Front Hum Neurosci       Date:  2017-01-11       Impact factor: 3.169

5.  Toward an Improved Multi-Criteria Drug Harm Assessment Process and Evidence-Based Drug Policies.

Authors:  Veljko Dubljević
Journal:  Front Pharmacol       Date:  2018-08-20       Impact factor: 5.810

6.  Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior.

Authors:  Eric Racine; Sebastian Sattler; Wren Boehlen
Journal:  Sci Eng Ethics       Date:  2021-03-23       Impact factor: 3.525

7.  The Complexity of Neuroenhancement and the Adoption of a Social Cognitive Perspective.

Authors:  Arnaldo Zelli; Fabio Lucidi; Luca Mallia
Journal:  Front Psychol       Date:  2015-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.